Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Design & aims of the EURO-SKI trial in CML

Francois-Xavier Mahon • 22 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia
EURO-SKI

Francois-Xavier Mahon, MD, PhD, University of Bordeaux, Bordeaux, France, briefly outlines the design and objectives of the EURO-SKI (NCT01596114) trial which aimed to better define the prognostic factors for treatment-free remission (TFR) in chronic myeloid leukemia (CML). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Francois-Xavier Mahon

Recommendations for treatment discontinuation in CML
2:18
Recommendations for treatment discontinuation in CML
Francois-Xavier Mahon • 22 Oct 2022
Key challenges in CML: QoL, managing CML in resource-challenged countries & achieving a cure
1:24
Key challenges in CML: QoL, managing CML in resource-challenged countries & achieving a cure
Francois-Xavier Mahon • 22 Oct 2022
Feasibility of treatment cessation in patients with CML with atypical BCR-ABL fusion transcripts
1:05
Feasibility of treatment cessation in patients with CML with atypical BCR-ABL fusion transcripts
Francois-Xavier Mahon • 26 Nov 2021
EURO-SKI: 3-year follow-up data of TKI cessation in CML
4:57
EURO-SKI: 3-year follow-up data of TKI cessation in CML
Francois-Xavier Mahon • 26 Nov 2021

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals